Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e26451f92f41ef29c46fb05fed88b823 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-686 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1866 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2020-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d81b50b1910c2daf4077e8a1a0ad9bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19e788b6e3f43d1072e5832b54baee28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_984268c0e188c4688bd5dda51404c9ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45e490ad05fb20634c6734ed798f50f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bd77fb2a3800ac364371522167b7eb3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd36c5af23c7460ce5bee189ee2ee1d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e79c8a924f499e803dee68aba71f752 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e16cc8d7c7c1f9482033264de489990 |
publicationDate |
2022-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CN-114502197-A |
titleOfInvention |
Treatment of diabetic retinopathy with a fully human post-translationally modified anti-VEGF Fab |
abstract |
Described are fully human post-translationally modified (HuPTM) monoclonal antibodies ("mAbs") or antigen-binding fragments of mAbs directed against human vascular endothelial growth factor ("hVEGF") - e.g., fully human glycosylated Antigen-binding (HuGly) Anti-hVEGF Antigen Binding Fragments - Compositions and methods for delivery to the retina/vitreal humour in the eye of a human subject diagnosed with diabetic retinopathy. |
priorityDate |
2019-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |